DELRAY BEACH, Fla., July 14, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today it has successfully created and laboratory-tested a stable and reproducible closed-cycle, continuous glucose sensing system that functions in the human blood fractions that are relevant to glucose analysis in the human body. PositiveID's development of the glucose sensor, which is based on RECEPTORS LLC's ("Receptors") proprietary chemistry platform, is a critical component of the Company's implantable RFID glucose-sensing microchip, GlucoChip™, which will accurately measure glucose levels in individuals with diabetes.
